JP2021515798A5 - - Google Patents
Info
- Publication number
- JP2021515798A5 JP2021515798A5 JP2020548991A JP2020548991A JP2021515798A5 JP 2021515798 A5 JP2021515798 A5 JP 2021515798A5 JP 2020548991 A JP2020548991 A JP 2020548991A JP 2020548991 A JP2020548991 A JP 2020548991A JP 2021515798 A5 JP2021515798 A5 JP 2021515798A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- seq
- amino acid
- acid sequence
- sequence described
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18161871.1 | 2018-03-14 | ||
| EP18161871 | 2018-03-14 | ||
| PCT/EP2019/056516 WO2019175368A1 (en) | 2018-03-14 | 2019-03-14 | Bispecific egfr/cd16 antigen-binding protein |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021515798A JP2021515798A (ja) | 2021-06-24 |
| JP2021515798A5 true JP2021515798A5 (enExample) | 2022-03-15 |
| JP7288913B2 JP7288913B2 (ja) | 2023-06-08 |
Family
ID=61683598
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020548991A Active JP7288913B2 (ja) | 2018-03-14 | 2019-03-14 | 二重特異性ｅｇｆｒ／ｃｄ１６抗原結合タンパク質 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11510972B2 (enExample) |
| EP (1) | EP3765157A1 (enExample) |
| JP (1) | JP7288913B2 (enExample) |
| KR (1) | KR102924742B1 (enExample) |
| CN (1) | CN111971090B (enExample) |
| AU (1) | AU2019235433B2 (enExample) |
| BR (1) | BR112020018492A2 (enExample) |
| CA (1) | CA3090464A1 (enExample) |
| IL (1) | IL276903B2 (enExample) |
| MX (1) | MX2020009445A (enExample) |
| SG (1) | SG11202007664WA (enExample) |
| WO (1) | WO2019175368A1 (enExample) |
| ZA (1) | ZA202006247B (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019175368A1 (en) * | 2018-03-14 | 2019-09-19 | Affimed Gmbh | Bispecific egfr/cd16 antigen-binding protein |
| CA3160927A1 (en) | 2019-12-27 | 2021-07-01 | Affimed Gmbh | Method for the production of bispecific fcyriii x cd30 antibody construct |
| US20250206823A1 (en) * | 2021-07-30 | 2025-06-26 | Qure Biotechnology (Shanghai) Co., Ltd. | Antigen targeting, anti-cd16a, and immune effector cell activating trifunctional fusion protein, and application thereof |
| WO2023036270A1 (zh) * | 2021-09-09 | 2023-03-16 | 启愈生物技术(上海)有限公司 | 抗原靶向、抗cd16a和免疫效应细胞激活三功能融合蛋白及其应用 |
| TW202330594A (zh) | 2021-09-29 | 2023-08-01 | 美商莫德斯醫療公司 | 抗原結合多肽、抗原結合多肽複合物及其使用方法 |
| WO2023079493A1 (en) * | 2021-11-03 | 2023-05-11 | Affimed Gmbh | Bispecific cd16a binders |
| TW202334221A (zh) * | 2021-11-03 | 2023-09-01 | 德商安富美德有限公司 | 雙特異性cd16a結合劑 |
| EP4562054A4 (en) * | 2022-07-28 | 2026-08-05 | Icahn School Med Mount Sinai | Anti-CD16A antibodies and their methods of use |
| KR20240136856A (ko) * | 2023-03-06 | 2024-09-19 | 주식회사 드노보 바이오테라퓨틱스 | 신규한 항-cd16 항체 및 이의 용도 |
| CN121100134A (zh) * | 2023-04-14 | 2025-12-09 | 山东先声生物制药有限公司 | 一种靶向人cd16和肿瘤抗原的多特异性抗体 |
| WO2025167357A1 (zh) * | 2024-02-06 | 2025-08-14 | 启愈生物技术(上海)有限公司 | Cd80/taa融合蛋白相关的肿瘤靶向、t细胞激活分子形式及其应用 |
| CN118221818B (zh) * | 2024-04-29 | 2025-01-24 | 四川大学 | 一种抗cd16a的纳米抗体及其应用 |
| WO2026017120A1 (zh) * | 2024-07-18 | 2026-01-22 | 信达生物制药(苏州)有限公司 | 抗cdh17/egfr/cd16a三特异性抗体及其用途 |
| CN118994409B (zh) * | 2024-07-30 | 2025-07-22 | 郑州市乘黄生物医药科技有限公司 | 结合CD16A和Trop2的双特异性抗体-NK细胞偶联物及其用途 |
| CN118791616A (zh) * | 2024-09-14 | 2024-10-18 | 苏州为度生物技术有限公司天津分公司 | 一种抗人cd16工程抗体及应用 |
| WO2026087751A1 (en) | 2024-10-24 | 2026-04-30 | Affimed Gmbh | Combination of immune cell engager and nk cell products |
| EP4751734A1 (en) | 2024-11-29 | 2026-06-03 | Affimed GmbH | Bispecific antibody construct dosage regimen for treating nsclc |
| EP4751731A1 (en) | 2024-11-29 | 2026-06-03 | Affimed GmbH | Combination of a bispecific antibody construct, an immune checkpoint inhibitor and a taxane |
| EP4751777A1 (en) | 2024-11-29 | 2026-06-03 | Affimed GmbH | Combination of a bispecific antibody construct, an immune checkpoint inhibitor and a vegfr-2 inhibitor |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0510790D0 (en) | 2005-05-26 | 2005-06-29 | Syngenta Crop Protection Ag | Anti-CD16 binding molecules |
| US8289183B1 (en) | 2008-04-25 | 2012-10-16 | Texas Instruments Incorporated | System and method for solar panel array analysis |
| PT2560993T (pt) | 2010-04-20 | 2024-09-16 | Genmab As | Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas |
| WO2011140254A1 (en) * | 2010-05-04 | 2011-11-10 | Adimab, Llc | Antibodies against epidermal growth factor receptor (egfr) and uses thereof |
| CN104203981A (zh) * | 2011-12-19 | 2014-12-10 | 合成免疫股份有限公司 | 双特异性抗体分子 |
| WO2014006217A1 (en) | 2012-07-06 | 2014-01-09 | Genmab B.V. | Dimeric protein with triple mutations |
| EP2970485A1 (en) * | 2013-03-15 | 2016-01-20 | Merck Patent GmbH | Tetravalent bispecific antibodies |
| CN105555804B (zh) * | 2013-08-07 | 2020-12-25 | 阿菲姆德股份有限公司 | 对EGFRvIII有特异性的抗体结合位点 |
| TWI731535B (zh) * | 2014-03-21 | 2021-06-21 | 美商艾伯維有限公司 | 抗-egfr抗體及抗體藥物結合物 |
| EP2930188A1 (en) * | 2014-04-13 | 2015-10-14 | Affimed Therapeutics AG | Trifunctional antigen-binding molecule |
| CA2983706C (en) * | 2015-05-04 | 2024-01-02 | Affimed Gmbh | Combination of a cd30xcd16 antibody with a pd-1 antagonist for therapy |
| EP3156417A1 (en) | 2015-10-13 | 2017-04-19 | Affimed GmbH | Multivalent fv antibodies |
| CN105367660B (zh) * | 2015-12-22 | 2018-12-21 | 深圳市北科生物科技有限公司 | 一种抗cd16a抗原和抗muc1抗原的双特异性抗体 |
| WO2019175368A1 (en) * | 2018-03-14 | 2019-09-19 | Affimed Gmbh | Bispecific egfr/cd16 antigen-binding protein |
-
2019
- 2019-03-14 WO PCT/EP2019/056516 patent/WO2019175368A1/en not_active Ceased
- 2019-03-14 SG SG11202007664WA patent/SG11202007664WA/en unknown
- 2019-03-14 CA CA3090464A patent/CA3090464A1/en active Pending
- 2019-03-14 JP JP2020548991A patent/JP7288913B2/ja active Active
- 2019-03-14 EP EP19715401.6A patent/EP3765157A1/en active Pending
- 2019-03-14 MX MX2020009445A patent/MX2020009445A/es unknown
- 2019-03-14 IL IL276903A patent/IL276903B2/en unknown
- 2019-03-14 AU AU2019235433A patent/AU2019235433B2/en active Active
- 2019-03-14 KR KR1020207029239A patent/KR102924742B1/ko active Active
- 2019-03-14 CN CN201980018525.9A patent/CN111971090B/zh active Active
- 2019-03-14 BR BR112020018492-6A patent/BR112020018492A2/pt unknown
-
2020
- 2020-09-02 US US17/010,622 patent/US11510972B2/en active Active
- 2020-10-08 ZA ZA2020/06247A patent/ZA202006247B/en unknown
-
2022
- 2022-10-19 US US18/047,917 patent/US12076384B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL276903B1 (en) | Bispecific egfr/cd16 antigen-binding protein | |
| JP2020180158A5 (enExample) | ||
| Lu et al. | Di-diabody: a novel tetravalent bispecific antibody molecule by design | |
| JP2021042257A5 (enExample) | ||
| TWI743461B (zh) | 具有交叉結合區定向之雙重可變區類抗體結合蛋白 | |
| JP2020063262A5 (enExample) | ||
| US12098203B2 (en) | Hetero-dimeric multi-specific antibody format targeting at least CD3 and HSA | |
| JP2017504578A5 (enExample) | ||
| JP2021503455A5 (enExample) | ||
| JP2023527609A5 (enExample) | ||
| JP2021508469A5 (enExample) | ||
| JP2021525546A5 (enExample) | ||
| JP2020508655A5 (enExample) | ||
| JP2020531438A5 (ja) | Ｎｋｇ２ｄ、ｃｄ１６、およびｈｌａ−ｅに結合するタンパク質 | |
| JP2018502050A5 (enExample) | ||
| JP2010502183A5 (enExample) | ||
| JP2013515508A5 (enExample) | ||
| JP2018522888A5 (enExample) | ||
| RU2015144098A (ru) | Четырехвалентные биспецифические антитела | |
| JP2025160226A5 (enExample) | ||
| JP2022545647A5 (enExample) | ||
| JP2021522347A5 (enExample) | ||
| JP2022504826A5 (enExample) | ||
| JP2023511376A5 (enExample) | ||
| RU2019134462A (ru) | Антитела, связывающиеся с steap-1 |